The low molecular weight heparinoid danaparoid sodium is an effective first-line treatment for heparin-induced thrombocytopenia. The drug is effective in >90% of treatment episodes and is associated with a low incidence of adverse events; however, few comparative data are available. Unlike low molecular weight heparins, danaparoid sodium has a low cross-reactivity with heparin-associated antiplatelet antibodies.
Recommendations for danaparoid sodium dosage and treatment duration vary according to the clinical status of the patient. Danaparoid sodium activity may be monitored by measuring plasma antifactor Xa levels; however, monitoring may not be necessary in all patients.